RxDoctor Payments Data

Francesca Ramos

Psychiatric/Mental Health · West Babylon, NYNPI 1184149114

Payments from drug & device makers

$5,403in general payments, 2019–2025

Across 202 payments — averaging $26.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$679
  • E.r. Squibb & Sons, L.L.C.$569
  • Neurocrine Biosciences, Inc.$568
  • Teva Pharmaceuticals USA, Inc.$520
  • Vanda Pharmaceuticals Inc.$494
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$5,28798%
  • Education$1162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,403 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$22,586
Medicare patients
24
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate29$80,799
LybalviOlanzapine/Samidorphan Malate16$24,630
TrintellixVortioxetine Hydrobromide12$4,769
Bupropion XlBupropion Hcl59$3,755
Aripiprazole67$3,442
Duloxetine Hcl60$1,700
Quetiapine Fumarate107$1,382
Hydroxyzine Hcl52$1,085
Olanzapine35$1,030
Haloperidol Decanoate27$1,027
Sertraline Hcl102$932
Fluoxetine Hcl46$876
Zolpidem Tartrate43$775
Mirtazapine47$757
Hydroxyzine Pamoate52$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$52$80,79929 claims
Alkermes, Inc.Lybalvi$1,112$24,63016 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$135$4,76912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in West Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →